Ekaterina Kalashnikova

Ekaterina Kalashnikova

Auto-generated profile, based on publicly available information

Ekaterina Kalashnikova

Natera, Inc, Austin, TX

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
Pashtoon Murtaza KasiPashtoon Murtaza Kasi
Pashtoon Murtaza Kasi
GFGordon Fehringer
Gordon Fehringer
HTHiroya Taniguchi
Hiroya Taniguchi
NSNaureen Starling
Naureen Starling
YNYoshiaki Nakamura
Yoshiaki Nakamura
SKScott Kopetz
Scott Kopetz
PURPOSE: Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS: We searched the literature using MEDLINE (via PubMed) for articles from January 1, 2000, focusing on studies that assessed ctDNA as a predictor of cancer recurrence. Broadly focused searches on ctDNA and cancer were also performed to provide additional background information. www.clinialtrials.gov was searched to identify trials that incorporate ctDNA testing. RESULTS: Numerous studies across different cancer types indicate that ctDNA-based MRD detection predicts recurrence with high sensitivity and specificity, and with lead times that precede standard imaging by up to 12 months. Recently, ctDNA testing has started being used to enroll MRD-positive patients at high risk of recurrence into trials, promising gains in statistical power that allow clinical utility to be demonstrated with smaller cohorts. Trials where ctDNA testing based-MRD detection is used to stratify patients into low or high-risk categories for treatment assignment are also ongoing. In addition, there is increasing evidence supporting the use of ctDNA dynamics or clearance as a surrogate end point, which could significantly reduce trial duration. CONCLUSION: ctDNA-based trial enrichment across many cancers seems likely to become increasingly common for cost- and time-reduction benefits. Trial efficiency could also benefit from using ctDNA as a surrogate end point, leading to accelerated approval of new therapeutics. A clear demonstration of efficacy from trials that use ctDNA-based MRD detection to assign treatment could transform clinical practice.

1 September 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
FCFrédéric Cailleux
Frédéric Cailleux
EAElisa Agostinetto
Elisa Agostinetto
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
FRFrançoise Rothé
Françoise Rothé
HWHsin-Ta Wu
Hsin-Ta Wu
MIMichail Ignatiadis
Michail Ignatiadis
PURPOSE: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy in patients with early-stage breast cancer may allow for early detection of relapse. In this study, we analyzed ctDNA using a personalized, tumor-informed multiplex polymerase chain reaction–based next-generation sequencing assay. METHODS: Plasma samples (n = 157) from 44 patients were collected before neoadjuvant therapy (baseline), after neoadjuvant therapy and before surgery (presurgery), and serially postsurgery including a last follow-up sample. The primary end point was event-free survival (EFS) analyzed using Cox regression models. RESULTS: Thirty-eight (86%), 41 (93%), and 38 (86%) patients had baseline, presurgical, and last follow-up samples, respectively. Twenty patients had hormone receptor–positive/human epidermal growth factor receptor 2–negative, 13 had triple-negative breast cancer, and 11 had human epidermal growth factor receptor 2–positive disease. Baseline ctDNA detection was observed in 22/38 (58%) patients and was significantly associated with Ki67 > 20% ( P = .036) and MYC copy-number gain ( P = .0025, false discovery rate = 0.036). ctDNA detection at presurgery and at last follow-up was observed in 2/41 (5%) and 2/38 (5%) patients, respectively. Eight relapses (seven distant and one local) were noted (median follow-up 3.03 years [range, 0.39-5.85 years]). After adjusting for pathologic complete response (pCR), ctDNA detection at presurgery and at last follow-up was associated with shorter EFS (hazard ratio [HR], 53; 95% CI, 4.5 to 624; P < .01, and HR, 31; 95% CI, 2.7 to 352; P < .01, respectively). Association between baseline detection and EFS was not observed (HR, 1.4; 95% CI, 0.3 to 5.9; P = .67). CONCLUSION: The presence of ctDNA after neoadjuvant chemotherapy is associated with relapse in early-stage breast cancer, supporting interventional trials for testing the clinical utility of ctDNA monitoring in this setting.

1 December 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
JSJacqui Shaw
Jacqui Shaw
KPKaren Page
Karen Page
EWEvie Wren
Evie Wren
EBElza C. de Bruin
Elza C. de Bruin
EKEkaterina Kalashnikova
Ekaterina Kalashnikova
RCR. Charles Coombes
R. Charles Coombes
PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data. RESULTS: Personalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival ( P < .0001) and overall survival ( P < .0001). All relapsing triple-negative patients (n = 7/23) had a ctDNA-positive test within a median of 8 months (range, 0-19 months), while the 16 nonrelapsed patients with triple-negative breast cancer remained ctDNA-negative during a median follow-up of 58 months (range, 8-99 months). The four patients who had negative tests before relapse all had hormone receptor–positive (HR+) disease and conversely, five of the 122 nonrelapsed patients (all HR+) had an occasional positive test. CONCLUSION: Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.

30 August 2024 in ESMO Open
Verified
Journal Article
Open access
RCR. Cutts
R. Cutts
LUL. Ulrich
L. Ulrich
MBM. Beaney
M. Beaney
MRM. Robert
M. Robert
MCM. Coakley
M. Coakley
IGI. Garcia-Murillas
I. Garcia-Murillas
In early breast cancer (EBC) patients, we aimed to determine whether circulating tumor DNA (ctDNA) analysis following primary surgery, before systemic therapy, identified molecular residual disease and was associated with risk of relapse and relapse-free survival (RFS). Plasma was collected, retrospectively, before surgery, 1-14 weeks post-operatively, and before adjuvant therapy, and in a subset of patients after adjuvant therapy. A personalized, tumor-informed, multiplex PCR next generation sequencing assay (Signatera™) was used for ctDNA detection and quantification. The primary objective was to compare RFS and distant recurrence-free survival (DRFS) in patients with detected versus non-detected ctDNA. A total of 48 patients with EBC (median age 50.5 years) [34 hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-), 5 HER2+, 9 triple-negative breast cancer) were included. ctDNA was detected in 64.5% (20/31) of patients before surgery, and 35.4% (17/48) after surgery. ctDNA detection before surgery was associated with tumor grade (P = 0.019), ctDNA detection after surgery was associated with receptor subtype (P = 0.01). Patients with ctDNA detected after surgery had worse DRFS [hazard ratio = 5.5, 95% confidence interval (CI) 1.1-28.5, P = 0.04]. RFS in patients with ctDNA detected after surgery was worse than in those with lack of ctDNA detection, although not statistically significant (hazard ratio = 3.7, 95% CI 0.9-15.7, P = 0.073). Patients with ctDNA detected preoperatively or post-operatively had a trend towards worse RFS (hazard ratio = 7.8, 95% CI 0.9-63.7, P = 0.05) and DRFS (hazard ratio = 6.8, 95% CI 0.8-57, P = 0.07) compared with those with ctDNA undetected at both timepoints. ctDNA detection anticipated clinical relapse with a median lead time of 16 months. In patients with treatment-naive EBC, ctDNA is detectable after surgery. The absence of ctDNA at a single post-surgical timepoint is associated with improved DRFS, supporting the development of future trials studying de-escalation of systemic therapy.

1 May 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
JFJulia Foldi
Julia Foldi
SOSteffi Oesterreich
Steffi Oesterreich
ATAntony Tin
Antony Tin
SRSamuel Rivero-Hinojosa
Samuel Rivero-Hinojosa
JFJanie Fielder
Janie Fielder
ALAdrian V. Lee
Adrian V. Lee
PURPOSE: Despite varying treatment responses and vastly different clinicopathologic characteristics, invasive lobular carcinoma (ILC) is treated similar to other subtypes of breast cancer. Serial personalized and tumor-informed, circulating tumor DNA (ctDNA) analysis may enable real-time treatment monitoring in metastatic ILC (mILC). METHODS: In this retrospective analysis of real-world data, we analyzed ctDNA longitudinally in 66 patients with mILC using a clinically validated, personalized, tumor-informed 16-plex polymerase chain reaction-next generation sequencing assay (Signatera). We evaluated the predictive value on survival of a single ctDNA test result and correlated ctDNA detection rates and on-treatment ctDNA dynamics with disease status. RESULTS: A total of 355 plasma samples were analyzed from 66 patients with mILC (median age at diagnosis, 62.6 years [range, 32.2-79.7 years]). On treatment, ctDNA dynamics correlated well with clinical response to treatment as assessed by imaging. Ninety-two percent (11 of 12) of patients with either ctDNA decrease (6 of 6) or no change in ctDNA levels (5 of 6) while on treatment showed clinical benefit from their prescribed regimen, whereas only 31% (4 of 13) of patients who showed an increase in their ctDNA had a clinical benefit on imaging. Finally, patients with a positive ctDNA test showed a greater probability of death compared with those with negative results, and the positive predictive value of ctDNA testing continued to increase exponentially with each positive result. Similarly, a negative ctDNA result was associated with 97% overall survival at 6 months and remained high (approximately 90%) at the 12-month follow-up. CONCLUSION: Serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.

1 October 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
PKPeter W. Ketch
Peter W. Ketch
CSCarly Bess Scalise
Carly Bess Scalise
FRFernando Recio
Fernando Recio
TBTara Berman
Tara Berman
NHNicole Hook
Nicole Hook
MTMichael D. Toboni
Michael D. Toboni
PURPOSE: Clinical decision making for adjuvant treatment in early-stage uterine cancer (UC) following surgery is typically directed by clinicopathological risk factors. There is an unmet need for a clinically relevant biomarker to improve individualized risk stratification and help monitor response to adjuvant therapy. Here, we sought to analyze circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with early-stage UC. METHODS: Retrospective analysis of ctDNA results from real-world data was performed for 61 patients (233 plasma time points) diagnosed with early-stage UC. ctDNA status and dynamics were assessed using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera), and its association with recurrence-free survival (RFS) was evaluated. RESULTS: ctDNA positivity was associated with significantly reduced RFS postoperatively (hazard ratio [HR], 7.6; P = .003) and postdefinitive therapy (HR, 25.4; P = .0009) and was the most significant factor associated with recurrence when compared with other clinicopathological and molecular risk factors. Notably, of patients who recurred and for whom clinical outcomes were available, 100% were ctDNA-positive before or at the time of recurrence, whereas none of the serially ctDNA-negative patients experienced relapse. CONCLUSION: Our data demonstrate the feasibility of monitoring ctDNA in the postoperative and adjuvant settings in early-stage UC. Analysis of ctDNA, in addition to other risk factors, may help identify patients at the highest risk of recurrence, inform surveillance strategies, and support treatment decision-making for these patients.